Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TECH | Bio-Techne Corporation

IndexS&P 500 P/E40.24 EPS (ttm)1.76 Insider Own0.80% Shs Outstand157.50M Perf Week-2.23%
Market Cap11.27B Forward P/E30.42 EPS next Y2.33 Insider Trans-6.56% Shs Float156.59M Perf Month-9.93%
Income285.20M PEG3.56 EPS next Q0.44 Inst Own97.90% Short Float / Ratio1.98% / 3.78 Perf Quarter-7.54%
Sales1.14B P/S9.91 EPS this Y6.30% Inst Trans1.95% Short Interest3.10M Perf Half Y-4.04%
Book/sh12.49 P/B5.67 EPS next Y19.00% ROA11.50% Target Price101.42 Perf Year-6.74%
Cash/sh1.28 P/C55.16 EPS next 5Y11.31% ROE15.30% 52W Range68.00 - 90.63 Perf YTD-14.49%
Dividend0.32 P/FCF52.12 EPS past 5Y23.60% ROI12.70% 52W High-21.81% Beta1.22
Dividend %0.45% Quick Ratio3.50 Sales past 5Y12.10% Gross Margin67.70% 52W Low4.22% ATR2.01
Employees3050 Current Ratio4.80 Sales Q/Q4.50% Oper. Margin30.60% RSI (14)31.48 Volatility2.88% 2.46%
OptionableYes Debt/Eq0.18 EPS Q/Q23.80% Profit Margin25.10% Rel Volume0.82 Prev Close70.63
ShortableYes LT Debt/Eq0.18 EarningsAug 08 BMO Payout17.60% Avg Volume821.54K Price70.87
Recom1.60 SMA20-6.50% SMA50-11.86% SMA200-11.03% Volume669,816 Change0.34%
Date Action Analyst Rating Change Price Target Change
Aug-28-23Initiated William Blair Outperform
Jan-10-23Upgrade Wells Fargo Underweight → Equal Weight $90
Dec-14-22Initiated Deutsche Bank Buy $100
Dec-12-22Upgrade Citigroup Neutral → Buy $81.25 → $100
Dec-07-22Initiated RBC Capital Mkts Sector Perform $89
Aug-25-22Initiated Credit Suisse Outperform $465
Apr-25-22Downgrade Wells Fargo Equal Weight → Underweight $370
Sep-15-21Upgrade KeyBanc Capital Markets Sector Weight → Overweight $600
Mar-08-21Upgrade Stephens Equal-Weight → Overweight $380 → $425
Feb-23-21Upgrade Stifel Hold → Buy $435
Sep-19-23 02:00AM
Sep-18-23 07:32PM
Sep-08-23 11:35AM
Sep-06-23 12:04PM
07:32PM Loading…
Aug-28-23 07:32PM
Aug-24-23 07:00AM
Aug-21-23 01:05PM
Aug-18-23 07:32PM
Aug-15-23 07:00AM
Aug-14-23 07:00AM
12:36PM Loading…
Aug-08-23 12:36PM
Aug-05-23 09:49AM
Jul-28-23 05:14PM
Jul-13-23 07:00AM
Jul-10-23 07:00AM
Jun-22-23 02:55PM
11:23AM Loading…
Jun-16-23 11:23AM
Jun-01-23 07:00AM
May-29-23 06:47AM
May-25-23 07:00AM
May-18-23 07:00AM
May-16-23 10:45AM
May-12-23 09:07AM
May-10-23 07:00AM
May-03-23 06:30AM
May-02-23 07:00AM
Apr-19-23 07:22PM
Apr-17-23 07:00AM
Apr-13-23 07:00AM
Apr-12-23 07:00AM
Apr-11-23 06:24AM
Apr-05-23 07:00AM
Apr-03-23 07:00AM
Mar-31-23 10:36AM
Mar-27-23 06:45AM
Mar-17-23 07:15AM
Mar-15-23 07:00AM
Mar-10-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 09:58AM
Feb-26-23 08:39AM
Feb-24-23 08:40AM
Feb-22-23 07:00AM
Feb-14-23 07:00AM
Feb-06-23 02:06AM
Feb-05-23 07:06AM
Feb-02-23 06:30AM
Jan-31-23 07:00AM
Jan-26-23 07:00AM
Jan-24-23 03:25PM
Jan-17-23 07:00AM
Jan-10-23 07:00AM
Jan-07-23 09:09AM
Dec-22-22 11:21AM
Dec-21-22 07:00AM
Dec-19-22 08:43AM
Dec-09-22 05:42PM
Dec-07-22 09:01AM
Dec-05-22 07:00AM
Dec-01-22 07:00AM
Nov-28-22 12:31PM
Nov-17-22 07:00AM
Nov-15-22 07:00AM
Nov-10-22 07:00AM
Nov-08-22 07:00AM
Nov-03-22 07:00AM
Nov-01-22 02:52PM
Oct-31-22 07:00AM
Oct-18-22 11:30AM
Oct-17-22 01:50PM
Oct-12-22 07:00AM
Oct-11-22 07:00AM
Oct-10-22 07:00AM
Oct-06-22 07:00AM
Sep-26-22 07:00AM
Sep-23-22 05:18PM
Sep-21-22 07:00AM
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nusse RoelandDirectorAug 30Option Exercise22.4032,000716,80060,811Sep 01 04:06 PM
Nusse RoelandDirectorAug 30Sale80.328,939717,95951,872Sep 01 04:06 PM
Kelderman KimPres. Diagnostics & GenomAug 24Option Exercise47.602,10099,96021,225Aug 28 04:19 PM
Kummeth Charles R.Chief Executive OfficerAug 15Option Exercise0.0017,63201,286,944Aug 17 04:14 PM
Kummeth Charles R.Chief Executive OfficerAug 05Option Exercise0.0051,51601,310,282Aug 08 05:31 PM
Hippel JamesCFOAug 05Option Exercise0.0012,876063,896Aug 08 05:29 PM
Kelderman KimPres. Diagnostics & GenomAug 05Option Exercise0.008,060023,264Aug 08 05:28 PM
Kummeth Charles R.Chief Executive OfficerJul 21Sale88.3680,0007,069,0241,258,766Jul 25 05:27 PM
Kummeth Charles R.Chief Executive OfficerJun 30Option Exercise26.65616,67616,434,4151,729,493Jul 05 06:38 PM
Kummeth Charles R.Chief Executive OfficerJun 07Sale83.0032226,7261,112,817Jun 09 04:07 PM
HIGGINS JOHN LDirectorApr 28Option Exercise21.8516,000349,60039,360May 02 04:49 PM
Kummeth Charles R.Chief Executive OfficerJan 04Option Exercise26.65407,36410,856,2511,368,976Jan 06 04:37 PM
Furlow Brenda S.SVP - GENERAL COUNSELDec 08Option Exercise31.267,450232,90633,542Dec 09 04:48 PM
Furlow Brenda S.SVP - GENERAL COUNSELDec 08Sale82.127,450611,81026,092Dec 09 04:48 PM
Furlow Brenda S.SVP - GENERAL COUNSELDec 07Option Exercise31.2680025,01026,892Dec 09 04:48 PM
Furlow Brenda S.SVP - GENERAL COUNSELDec 07Sale82.0180065,60526,092Dec 09 04:48 PM